Moderna wins Nasdaq-100 inclusion, Warner Bros. Discovery out
Moderna (MRNA) will join the Nasdaq-100 index on 9 October 2026, replacing Warner Bros. Discovery (WBD) due to its pending acquisition. Moderna's shares rose 42.12% in 20 trading days, driven by positive trial data for a melanoma vaccine, despite reporting net losses. WBD's exit is due to its merger with Paramount Skydance, not underperformance.
How this was made

The 30-second read
Why it matters
The inclusion/exclusion will cause mechanical buying/selling by passive funds, potentially amplifying price moves beyond fundamentals.
Market read
Index rebalancing creates short‑term trading opportunities for both stocks as funds adjust holdings.
What to watch
Fund managers may weigh the company's loss streak and trial risk against index‑driven buying.
Background
Nasdaq-100 composition changes are periodic and driven by market cap and liquidity; this move reflects Moderna's recent price surge and WBD's pending merger.
Ticker impact
Moderna is added to the Nasdaq-100 effective 9 Oct, triggering passive fund buying and supporting its recent 42% rally.
upward as passive funds buy on inclusion
Nasdaq-100 inclusion forces fund rebalancing, historically boosting added stocks.
Warner Bros. Discovery is removed from the Nasdaq-100 ahead of its pending Paramount Skydance acquisition, prompting fund outflows.
downward as passive funds sell on removal
Removal from a major index forces tracking funds to liquidate positions.
Market effects
Highlights the weight of biotech in the Nasdaq-100 and may shift sector allocations.
U.S. equity indices adjust as two large‑cap constituents change.
Index rebalancing can affect global fund flows and ETFs tracking the Nasdaq-100.
Counterpoint
Despite the inclusion, Moderna's ongoing losses suggest caution; the rally may be speculative.
Key entities
- companyModerna
Biotech firm added to Nasdaq-100
- companyWarner Bros. Discovery
Media company removed from Nasdaq-100



